Head to Head Survey: Keen Vision Acquisition (NASDAQ:KVAC) vs. Edesa Biotech (NASDAQ:EDSA)

Edesa Biotech (NASDAQ:EDSA) and Keen Vision Acquisition (NASDAQ:KVAC) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, earnings, institutional ownership, valuation, dividends and risk.

Profitability

This table compares Edesa Biotech and Keen Vision Acquisition’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Edesa Biotech	N/A	-560.22%	-105.74%
Keen Vision Acquisition	N/A	N/A	N/A

Risk & Volatility

Edesa Biotech has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Keen Vision Acquisition has a beta of -0.04, meaning that its share price is 104% less volatile than the S&P 500.

Insider and Institutional Ownership

5.5% of Edesa Biotech shares are held by institutional investors. Comparatively, 51.7% of Keen Vision Acquisition shares are held by institutional investors. 24.4% of Edesa Biotech shares are held by insiders. Comparatively, 80.2% of Keen Vision Acquisition shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Earnings and Valuation

This table compares Edesa Biotech and Keen Vision Acquisition”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edesa Biotech	N/A	N/A	-$7.19 million	($1.69)	-2.60
Keen Vision Acquisition	N/A	N/A	N/A	N/A	N/A

Analyst Recommendations

This is a summary of current recommendations for Edesa Biotech and Keen Vision Acquisition, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edesa Biotech	1	0	1	1	2.67
Keen Vision Acquisition	0	1	0	0	2.00

Edesa Biotech presently has a consensus price target of $5.00, indicating a potential upside of 13.64%. Given Edesa Biotech’s stronger consensus rating and higher possible upside, research analysts clearly believe Edesa Biotech is more favorable than Keen Vision Acquisition.

Summary

Edesa Biotech beats Keen Vision Acquisition on 5 of the 9 factors compared between the two stocks.

About Edesa Biotech

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

About Keen Vision Acquisition

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.